Use of Markers in Defining Urothelial Premalignant and Malignant Conditions

REFERENCES

• Hamden P. Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 1999; 353: 974–7.
   Google Scholar
• Koss LG, Tiamson EM, Robbins MA. Mapping cancerous and precancerous bladder changes. A study of the urothelium in ten surgically removed bladders. JAMA 1974; 227: 281–6.
   Google Scholar
• Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999; 23: 443–7.
   PubMed Web of Science ®Google Scholar
• Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Usui T, et al. A mapping of histology and cell pro-liferation in human bladder cancer: an immunohisto-chemical study. Hiroshima J Med Sci 1995; 44: 93–7.
   PubMedGoogle Scholar
• Lee E, Schwaibold H, Fradet Y, Huland E, Huland H. Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladder. J Urol 1997; 157: 1070–3.
   Google Scholar
• Rao JY, Hemstreet III GP, Hurst RE, Bonner RB, Jones PL, Min KW, et al. Alterations in phenotypic biochemi-cal markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sci USA 1993; 90: 8287–91.
   PubMed Web of Science ®Google Scholar
• Celis JE, Celis P. Ostergaard M, Basse B, Lauridsen JB, Ratz G, et al. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res 1999; 59: 3003–9.
   PubMed Web of Science ®Google Scholar
• Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999; 154: 721–7.
   PubMed Web of Science ®Google Scholar
• Hemstreet III GP, Rao J, Hurst RE, Bonner RB, Waliszewski P, Grossman HB, et al. G-actin as a risk factor and modulatable endpoint for cancer chemopre-vention trials. J Cell Biochem Suppl 1996; 25: 197-204. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999; 162: 53–7.
   Google Scholar
• Fradet Y, Lafleur L, LaRue H. Strategies of chemopre-vention based on antigenic and molecular markers of early and premalignant lesions of the bladder. J Cell Biochem Suppl 1992; 161: 85–92.
   Google Scholar
• Fradet Y, Lockhart C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt. Can J Urol 1997; 4: 400–5.
   PubMedGoogle Scholar
• Grossman HB, Washington Jr RW, Carey TE, Liebert M. Alterations in antigen expression in superficial bladder cancer. J Cell Biochem Suppl 1992; 161: 63-8. Bonner RB, Liebert M, Hurst RE, Grossman HB, Bane BL, Hemstreet III GP. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Cancer Epidemiol Biomar-kers Prey 1996; 5: 971–8.
   Google Scholar
• Senga Y, Kimura G, Hattori T, Yoshida K. Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer. Urology 1996; 48: 703–10.
   PubMed Web of Science ®Google Scholar
• Pariente JL, Bordenave L, Michel P. Latapie MJ, Ducassou D, LeGuillou M. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 1997; 158: 338–41.
   Google Scholar
• Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Espasa A, Chinchilla V, et al. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder. J Urol 1999; 161: 1110–5.
   Google Scholar
• Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide anti-gen and NMP22 to detect bladder cancer. J Urol 1999; 162: 1951–6.
   Google Scholar
• Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997; 158: 801–5.
   PubMed Web of Science ®Google Scholar
• Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997; 158: 2098–101.
   PubMed Web of Science ®Google Scholar
• Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997; 158: 801�5.
   Web of Science ®Google Scholar
• Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997; 158: 2098�101.
   Web of Science ®Google Scholar
• Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere White RW, Sheinfeld J, et al. Detection of recurrent bladder cancer using a new one-step test for bladder tumor antigen. J Urol 1997; 157 (Suppl): 337.
   Google Scholar
• Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 1997; 50: 882�7.
   Web of Science ®Google Scholar
• Pode D, Shapiro A, Wald M, Nativ O, Laufer M, KaverI. Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999; 161: 443�6.
   Web of Science ®Google Scholar
• Abbate I, D'Introno A, Cardo G, Marano A, Addabbo L, Musci MD, et al. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer. Anticancer Res 1998; 18: 3803–5.
   PubMed Web of Science ®Google Scholar
• Sheinfeld J, Reuter VE, Melamed MR, Fair WR, Morse M, Sogani PC, et al. Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 1990; 143: 285–8.
   PubMed Web of Science ®Google Scholar
• Schmitz-Dräger BJ, Nakamura S, Decken K, Pfitzer P. Rottmann-IcIder C, Ebert T, et al. Monoclonal antibody Due ABC 3 directed against transitional cell carcinoma. II. Prospective trial on the diagnostic value ofimmunocytology using monoclonal antibody Due ABC 3. J Urol 1991; 146: 1521–4.
   Google Scholar
• Pode D, Golijanin D, Sherman Y, Lebensart P, Shapiro A. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 1998; 159: 389–92.
   Google Scholar
• Planz B, Striepecke E, Jakse G, Bocking A. Use of Lewis X antigen and deoxyribonucleic acid image cytometry to increase sensitivity of urinary cytology in transitional cell carcinoma of the bladder. J Urol 1998; 159: 384–7.
   PubMed Web of Science ®Google Scholar
• Sagerman PM, Saigo PE, Sheinfeld J, Charitonowics E, Cordon-Cardo C. Enhanced detection of bladder cancer in urine cytology with Lewis X, M344 and 19A211 antigens. Acta Cytol 1994; 38: 517–23.
   Google Scholar
• Loy TS, Alexander CJ, Calaluce RD. Lewis X antigen immunostaining in the diagnosis of transitional cell carcinoma. Mod Pathol 1995; 8: 587–90.
   Google Scholar
• Jankevicius F, Shibayama T, Decken K, Bojar H, Gerharz CD, Ebert T, et al. Dual-parameter immunoflow cytometry in diagnosis and follow-up of patients with bladder cancer. Eur Urol 1998; 34: 492–9.
   PubMed Web of Science ®Google Scholar
• Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer 1999; 87: 118–28.
   PubMed Web of Science ®Google Scholar
• Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer. Urol Clin N Am 1992; 19: 435–53.
   Google Scholar
• Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 1990; 21: 886–96.
   PubMed Web of Science ®Google Scholar
• Shenoy UA, Colby TV, Schumann GB. Reliability of urinary cytodiagnosis in urothelial neoplasms. Cancer 1985; 56: 2041–5.
   Google Scholar
• Schwalb DM, Herr HW, Fair WR. The management of clinically unconfirmed positive urinary cytology. J Urol 1993; 150: 1751–6.
   Google Scholar
• Badalament RA, Hermansen DK, Kimmel M, Gay H, Herr HW, Fair WR, et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 1987; 60: 1423–7.
   PubMed Web of Science ®Google Scholar
• de la Roza GL, Hopkovitz A, Caraway NP, Kidd L, Dinney CP, Johnston D, et al. DNA image analysis of urinary cytology: prediction of recurrent transitional cell carcinoma. Mod Pathol 1996; 9: 571–8.
   PubMed Web of Science ®Google Scholar
• Slaton JVV, Dinney CPN, Veltri RW, Miller MC, Liebert M, O'Dowd GJ, et al. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transi-tional cell carcinoma of the bladder. J Urol 1997; 158: 806–11.
   Google Scholar
• Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996; 156: 1280–5.
   PubMed Web of Science ®Google Scholar
• Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997; 31: 163–8.
   PubMed Web of Science ®Google Scholar
• Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; 156: 363–7.
   PubMed Web of Science ®Google Scholar
• Serretta V, Lo Presti D, Vasile P. Gange E, Esposito E, Menozzi I. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 1998; 52: 793–6.
   Google Scholar
• Stampfer DS, Carpinito GA, RodriguezVillanueva J, Willsey LW, Dinney CP, Grossman HB, et al. Evalua-tion of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998; 159: 394–8.
   PubMed Web of Science ®Google Scholar
• Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 1999; 161: 62–5.
   Google Scholar
• Ramakumar S, Bhuiyan J, Besse JA, Roberts SC, Wollan PC, Blute ML, et al. Comparison of screening methods in detection of bladder cancer. J Urol 1999; 161: 388–94.
   PubMed Web of Science ®Google Scholar
• Hemstreet III GP, Rao J, Hurst RE, Bonner RB, Mellott JE, Rooker GM. Biomarkers in monitoring for efficacy of immunotherapy and chemoprevention of bladder cancer with dimethylsulfoxide. Cancer Detect Prey 1999; 23: 163–71.
   PubMedGoogle Scholar
• Malik SN, Murphy WM. Monitoring patients for bladder neoplasms: what can be expected of urinary cytology consultations in clinical practice. Urology 1999; 54: 62–6.
   PubMed Web of Science ®Google Scholar
• Zieger K, Wolf H, Olsen PR, Hojgaard K. Long-term follow-up of noninvasive bladder tumour s(stage Ta): recurrence and progression. Br J Urol Int 2000; 85: 824–8.
   Google Scholar
• Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000; 163: 60–1.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, Ti and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study. J Urol 2000; 163: 1124–9.
   PubMed Web of Science ®Google Scholar
• Esrig D, Spruck III CH, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389–97.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994; 56: 347–53.
   Google Scholar
• Abdel-Fattah R, Challen C, Griffiths TRL, Robinson MC, Neal DE, Lunec J. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998; 77: 2230–8.
   Google Scholar
• Gao JP, Uchida T, Wang CX, Jiang SX, Matsumoto K, Satoh T, et al. Relationship between p53 gene mutation and protein expression: Clinical significance in transi-tional cell carcinoma of the bladder. Int J Oncol 2000; 16: 469–75.
   PubMed Web of Science ®Google Scholar
• Lipponen PK. Over-expression of p53 nuclear oncopro-tein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993; 53: 365–70.
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85: 53–9.
   Google Scholar
• Sarkis AS, Zhang ZF, Cordon-Cardo C, Melamed J, Dalbagni G, Sheinfeld J, et al. p53 nuclear over-expression and disease progression in Ta bladder carcinoma. Int J Oncol 1993; 3: 355–60.
   Google Scholar
• Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994; 152: 388–92.
   Google Scholar
• Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259–64.
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13: 1384–90.
   PubMed Web of Science ®Google Scholar
• Kuczyk MA, Bokemeyer C, Serth J, Hervatin C, Oelke M, Hofner K, et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995; 31A: 2243–7.
   PubMed Web of Science ®Google Scholar
• Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan IIK, et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995; 71: 201–5.
   PubMed Web of Science ®Google Scholar
• Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p21(WAF1/ CIP1) expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072–9.
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992; 84: 1256–61.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84: 1251–6.
   PubMed Web of Science ®Google Scholar
• Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58: 1090–4.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, et al. p53 and RB expression predict progression in Ti bladder cancer. Clin Cancer Res 1998; 4: 829–34.
   PubMed Web of Science ®Google Scholar
• Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czemiak B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999; 18: 1197–203.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217–21.
   Google Scholar
• Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga ML, Seymour GJ, et al. Immunohistologi-cal expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol 1994; 73: 526–32.
   PubMedGoogle Scholar
• Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM, Schalken JA. p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 1994; 70: 496–500.
   PubMed Web of Science ®Google Scholar
• Jahnson S, Risberg B, Karlsson MG, Westman G, Bergstrom R, Pedersen J. p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Urol 1995; 28: 135–42.
   PubMed Web of Science ®Google Scholar
• Jahnson S, Karlsson MG. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy. J Urol 1998; 160: 1291–6.
   PubMed Web of Science ®Google Scholar
• Cheng L, Cheville JC, Neumann RM, Bostwick DG. Flat intraepithelial lesions of the urinary bladder. Cancer 2000; 88: 625–31.
   PubMed Web of Science ®Google Scholar
• Cheng L, Cheville JC, Neumann RM, Leibovich BC, Egan KS, Spoils BE, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999; 85: 2469–74.
   PubMed Web of Science ®Google Scholar
• Gustafson H, Tribukait B, Esposti PL. The prognostic value of DNA analysis in primary carcinoma in situ of the urinary bladder. Scand J Urol Nephrol 1982; 16: 141–6.
   Google Scholar
• Lacombe L, Dalbagni G, Zhang ZF, CordonCardo C, Fair WR, Herr HW, et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: correlation to clinical outcome. J Clin Oncol 1996; 14: 2646–52.
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1999; 161: 1124–7.
   PubMed Web of Science ®Google Scholar
• Pages F, Flam TA, Vieillefond A, Molinie V, Abeille X, Lazar V, et al. p53 status does not predict initial clinical response to Bacillus Calmette-Guerin intravesical ther-apy in Ti bladder tumors. J Urol 1998; 159: 1079–84.
   PubMed Web of Science ®Google Scholar
• Lebret T, Becette V, Barbagelatta M, Herve JM, Gaudez F, Barre P. et al. Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol 1998; 159: 788–91.
   PubMed Web of Science ®Google Scholar
• Okamura T, Akita H, Kawai N, Tozawa K, Yamada Y, Kohri K. Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bc1-2 expression during bacillus Calmette-Guerin (BCG) intravesical instillation therapy for superficial bladder cancers. Urol Res 1998; 26: 161–4.
   PubMedGoogle Scholar
• Zlotta AR, Noel JC, Fayt I, Drowart A, VanVooren JP, Huygen K, et al. Correlation and prognostic significance of p53, A21(WAF1/CIP1) and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 1999; 161: 792–8.
   PubMed Web of Science ®Google Scholar
• Ick K, Schultz M, Stout P, Fan K. Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment. Urology 1997; 49: 541–6.
   PubMed Web of Science ®Google Scholar
• Pfister C, Flaman JM, Dunet F, Grise P. Frebourg T. p53 mutations in bladder tumors inactivate the transactiva-tion of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. J Urol 1999; 162: 69–73.
   Google Scholar
• McShane LM, Aamodt R, Cordon-Cardo C, Cote R, Faraggi D, Fradet Y, et al. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 2000; 6: 1854–64.
   Google Scholar
• Ranefall P. Wester K, Andersson AC, Busch C, Bengtsson E. Automatic quantification of immunohisto-chemically stained cell nuclei based on standard reference cells. Anal Cell Pathol 1998; 17: 111–23.
   Google Scholar
• Wester K, Andersson AC, Ranefall F, Bengtsson E, Malmstrom PU, Busch C. Cultured human fibroblasts in agarose gel as a multi-functional control for immuno-histochemistry. Standardization of Ki67 (MIBI) assess-ment in routinely processed urinary bladder carcinoma tissue. J Pathol 2000; 190: 503–11.
   Google Scholar
• Catanzaro A, Perry S, Clarridge JE, Dunbar S, Good-night-White S, LoBue PA, et al. The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial. JAMA 2000; 283: 639–45.
   Google Scholar